Effect of Aurora-A expression on biochemical cure after surgery for Medullary carcinoma

【Abstract】 Background The relationship between the expression level of Aurora-A in Medullary thyroid carcinoma (MTC) tissues and the clinical case data and biochemical cure of medullary thyroid cancer patients is still unclear. Objective To analyze the relationship between Aurora-A expression in medullary thyroid tissue and the clinicopathological characteristics of patients, to further analyze the risk factors for biochemical cure, and to clarify the correlation between Aurora-A expression and biochemical cure. Methods A total of 90 patients with medullary cancer who were hospitalized and operated in the Department of Thyroid, Head and Neck Oncology of Tianjin Medical University Cancer Hospital from February 2011 to July 2019 were enrolled. Aurora-A immunohistochemical staining was performed on the pathological specimens of 90 patients undergoing

[1]  N. Margaryan,et al.  Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors , 2021, Oncogene.

[2]  M. Segura,et al.  Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer , 2020, Cancers.

[3]  K. Lorenz,et al.  Prediction of biochemical cure in patients with medullary thyroid cancer , 2020, The British journal of surgery.

[4]  P. Vestergaard,et al.  Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997–2014: A Nationwide Study , 2019, Thyroid : official journal of the American Thyroid Association.

[5]  J. Koo,et al.  Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck , 2019, Clinical Cancer Research.

[6]  P. Hou,et al.  c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[7]  A. Miyauchi,et al.  Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan , 2018, World Journal of Surgery.

[8]  Xiangqian Zheng,et al.  Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration , 2018, Oncogene.

[9]  B. Burkey,et al.  PROGNOSTIC VARIABLES AFFECTING PRIMARY TREATMENT OUTCOME FOR MEDULLARY THYROID CANCER. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[10]  Yan-fen Fang,et al.  Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases , 2016, Journal of Experimental & Clinical Cancer Research.

[11]  F. Peng,et al.  Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy , 2016, Medicinal research reviews.

[12]  W. Chung,et al.  Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence‐free survival of medullary thyroid cancer: a large‐scale retrospective analysis over 30 years , 2016, Clinical endocrinology.

[13]  R. Ciampi,et al.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma , 2016, Nature Reviews Endocrinology.

[14]  S. Morrone,et al.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line , 2016, Endocrine.

[15]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[16]  Kathryn J. Rowland,et al.  Biochemical Cure after Reoperations for Medullary Thyroid Carcinoma: A Meta-analysis , 2014, Annals of Surgical Oncology.

[17]  G. Donofrio,et al.  Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL. , 2013, Blood.

[18]  Quentin Liu,et al.  Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells , 2011, Journal of Translational Medicine.

[19]  M. Shah,et al.  Targeting RET Receptor Tyrosine Kinase Activation in Cancer , 2010, Clinical Cancer Research.

[20]  J. Moley,et al.  Medullary thyroid carcinoma: Management of lymph node metastases , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  C. Eisenberger,et al.  Long-Term Clinical and Biochemical Follow-up in Medullary Thyroid Carcinoma: A Single Institution's Experience Over 20 Years , 2007, Annals of surgery.

[22]  J. Reis-Filho,et al.  Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. , 2007, Cancer research.

[23]  Huan Yang,et al.  Aurora‐A induces cell survival and chemoresistance by activation of Akt through a p53‐dependent manner in ovarian cancer cells , 2006, International journal of cancer.

[24]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[25]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.